|Bid||98.75 x 900|
|Ask||120.00 x 1000|
|Day's Range||104.30 - 107.97|
|52 Week Range||29.46 - 108.00|
|PE Ratio (TTM)||59.63|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
The Watertown, Massachusetts-based company said it had profit of 61 cents per share. The biotechnology company posted revenue of $44 million in the period. Enanta Pharmaceuticals shares have increased ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) as an investment opportunity. If youRead More...
ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.
In 1Q18, Enanta Pharmaceuticals (ENTA) generated total revenues of $38.1 million compared with $10.4 million in 1Q17. The company derives revenues from royalties and milestone payments under its collaboration agreement with AbbVie (ABBV).
Enanta Pharmaceuticals (ENTA) is working on multiple compounds that selectively bind to and activate the farnesoid X receptor (or FXR). As the company’s lead FXR agonist, EDP-305 is designed to take advantage of increased binding interactions with the receptor.
Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.
Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).
Edge Therapeutics (EDGE) plummeted significantly after the company announced discontinuation of the pivotal late stage study on lead candidate.